Antiangiogenic and Anticancer Properties of Bifunctional Ruthenium(II)-p-Cymene Complexes: Influence of Pendant Perfluorous Chains

被引:26
作者
Nowak-Sliwinska, Patrycja [1 ,2 ]
Clavel, Catherine M. [2 ]
Paunescu, Emilia [2 ]
te Winkel, Marije T. [1 ,2 ]
Griffioen, Arjan W. [1 ]
Dyson, Paul J. [2 ]
机构
[1] Vrije Univ Amsterdam Med Ctr, Dept Med Oncol, Angiogenesis Lab, NL-1007 MB Amsterdam, Netherlands
[2] Swiss Fed Inst Technol EPFL, Inst Chem Sci & Engn, CH-1015 Lausanne, Switzerland
基金
瑞士国家科学基金会;
关键词
antiangiogenesis; bioorganometallic chemistry; CAM model; colorectal adenocarcinoma; ovarian carcinoma; ruthenium(II)-arene complexes; fluorine chemistry; IN-VIVO EVALUATION; NAMI-A; ANGIOGENESIS INHIBITION; RUTHENIUM COMPLEXES; ENDOTHELIAL-CELLS; SERUM-ALBUMIN; PHASE-I; BINDING; TRANSFERRIN; THERAPY;
D O I
10.1021/acs.molpharmaceut.5b00417
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Two bifunctional ruthenium(II)-p-cymene complexes with perfluorinated side chains, attached via pyridine ligands, have been evaluated in a series of in vitro and in vivo assays. Their effects on human endothelial (ECRF24 and HUVEC) cells, noncancerous human embryonic kidney (HEK-293) cells, and various human tumor cells were investigated. The complex with the shorter chain, 1, inhibits the proliferation of the tumor cell lines and ECRF24, whereas 2 selectively inhibits ECRF24 and HUVEC proliferation. Neither inhibits the migration of ECRF24 cells whereas both compounds inhibit sprout formation in HUVEC cells. Using three preclinical models, i.e., vasculature formation in the chorioallantoic membrane (CAM) of the chicken embryo, human A2780 ovarian carcinoma tumors xenografted on the CAM, and human LS174T colorectal adenocarcinoma tumors grown in athymic mice, the angiostatic and anticancer activities of these two complexes were studied. Overall, 1 inhibited tumor growth predominantly through an anticancer effect whereas 2 inhibited tumor growth predominately via an antiangiogenic mechanism.
引用
收藏
页码:3089 / 3096
页数:8
相关论文
共 50 条
  • [1] Imidazoacridinone-dependent lysosomal photodestruction: a pharmacological Trojan horse approach to eradicate multidrug-resistant cancers
    Adar, Y.
    Stark, M.
    Bram, E. E.
    Nowak-Sliwinska, P.
    van den Bergh, H.
    Szewczyk, G.
    Sarna, T.
    Skladanowski, A.
    Griffioen, A. W.
    Assaraf, Y. G.
    [J]. CELL DEATH & DISEASE, 2012, 3 : e293 - e293
  • [2] Ligand substitutions between ruthenium-cymene compounds can control protein versus DNA targeting and anticancer activity
    Adhireksan, Zenita
    Davey, Gabriela E.
    Campomanes, Pablo
    Groessl, Michael
    Clavel, Catherine M.
    Yu, Haojie
    Nazarov, Alexey A.
    Yeo, Charmian Hui Fang
    Ang, Wee Han
    Droege, Peter
    Rothlisberger, Ursula
    Dyson, Paul J.
    Davey, Curt A.
    [J]. NATURE COMMUNICATIONS, 2014, 5
  • [3] [Ru(η6-p-cymene)Cl2(pta)] (pta=1,3,5-triaza-7-phosphatricyclo[3.3.1.1]decane):: a water soluble compound that exhibits pH dependent DNA binding providing selectivity for diseased cells
    Allardyce, CS
    Dyson, PJ
    Ellis, DJ
    Heath, SL
    [J]. CHEMICAL COMMUNICATIONS, 2001, (15) : 1396 - 1397
  • [4] Ang W. H., 2007, NOVEL STRATEGIES OVE
  • [5] Target profiling of an antimetastatic RAPTA agent by chemical proteomics: relevance to the mode of action
    Babak, Maria V.
    Meier, Samuel M.
    Huber, Kilian V. M.
    Reynisson, Johannes
    Legin, Anton A.
    Jakupec, Michael A.
    Roller, Alexander
    Stukalov, Alexey
    Gridling, Manuela
    Bennett, Keiryn L.
    Colinge, Jacques
    Berger, Walter
    Dyson, Paul J.
    Superti-Furga, Giulio
    Keppler, Bernhard K.
    Hartinger, Christian G.
    [J]. CHEMICAL SCIENCE, 2015, 6 (04) : 2449 - 2456
  • [6] Ruthenium complexes can target determinants of tumour malignancy
    Bergamo, A.
    Sava, G.
    [J]. DALTON TRANSACTIONS, 2007, 13 (13) : 1267 - 1272
  • [7] Approaching tumour therapy beyond platinum drugs Status of the art and perspectives of ruthenium drug candidates
    Bergamo, A.
    Gaiddon, C.
    Schellens, J. H. M.
    Beijnen, J. H.
    Sava, G.
    [J]. JOURNAL OF INORGANIC BIOCHEMISTRY, 2012, 106 (01) : 90 - 99
  • [8] Biological role of adduct formation of the ruthenium(III) complex NAMI-A with serum albumin and serum transferrin
    Bergamo, A
    Messori, L
    Piccioli, F
    Cocchietto, M
    Sava, G
    [J]. INVESTIGATIONAL NEW DRUGS, 2003, 21 (04) : 401 - 411
  • [9] Modulation of the metastatic progression of breast cancer with an organometallic ruthenium compound
    Bergamo, Alberta
    Masi, Alessia
    Dyson, Paul J.
    Sava, Gianni
    [J]. INTERNATIONAL JOURNAL OF ONCOLOGY, 2008, 33 (06) : 1281 - 1289
  • [10] Cloning an artificial gene encoding angiostatic anginex: From designed peptide to functional recombinant protein
    Brandwijk, RJMGE
    Nesmelova, I
    Dings, RPM
    Mayo, KH
    Thijssen, VLJL
    Griffioen, AW
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2005, 333 (04) : 1261 - 1268